Treating Syrian refugees with diabetes and hypertension in Shatila refugee camp, Lebanon: Médecins Sans Frontières model of care and treatment outcomes

Maysoon Kayali1, Krystel Moussally2*, Chantal Lakis3, Mohamad Ali Abrash1, Carla Sawan4, Anthony Reid5 and Jeffrey Edwards5,6

Abstract

Background: Médecins Sans Frontières (MSF) has been providing primary care for non-communicable diseases (NCDs), which have been increasing in low to middle-income countries, in the Shatila refugee camp, Beirut, Lebanon, using a comprehensive model of care to respond to the unmet needs of Syrian refugees. The objectives of this study were to: 1) describe the model of care used and the Syrian refugee population affected by diabetes mellitus (DM) and/or hypertension (HTN) who had ≥ one visit in the MSF NCD clinic in Shatila in 2017, and 2) assess 6 month treatment outcomes.

Methods: A descriptive retrospective cohort study using routinely collected program data for a model of care for patients with DM and HTN consisting of four main components: case management, patient support and education counseling, integrated mental health, and health promotion.

Results: Of 2644 Syrian patients with DM and/or HTN, 8% had Type-1 DM, 30% had Type-2 DM, 30% had HTN and 33% had DM + HTN. At intake, patients had a median age of 53, were predominantly females (63%), mostly from outside the catchment area (70%) and diagnosed (97%) prior to enrollment. After 6 months of care compared to intake: 61% of all patients had controlled DM (HbA1C < 8%) and 50% had controlled blood pressure (BP: < 140/90 mmHg) compared to 29 and 32%, respectively (p < 0.001). Compared to intake, patients with Type-1 DM reached an HbA1C mean of 8.4% versus 9.3% (p = 0.022); Type-2 DM patients had an HbA1C mean of 8.1% versus 9.4% (p = 0.001); and those with DM + HTN reached a mean HbA1C of 7.7% versus 9.0%, (p = 0.003). Reflecting improved control, HTN patients requiring ≥3 medications increased from 23 to 38% (p < 0.001), while DM patients requiring insulin increased from 21 to 29% (p < 0.001). Loss-to-follow-up was 16%.

Conclusions: The MSF model of care for DM and HTN operating in the Shatila refugee camp is feasible, and showed promising outcomes among enrolled individuals. It may be replicated in similar contexts to respond to the increasing burden of NCDs among refugees in the Middle-East and elsewhere.

Keywords: Non-communicable disease, Refugee, Médecins Sans Frontières, Diabetes, Hypertension, Syrians
Background
Non-communicable diseases (NCDs) are leading causes of morbidity and mortality globally [1]. Their prevalence and burden are projected to continuously increase, with a more pronounced increase in low to middle-income countries such as Lebanon [2, 3], where an estimated 1.5 million Syrians have been displaced following the onset of the Syrian war in 2011 [4], creating a crisis situation in the country and a huge burden on the Lebanese health care system including that for NCDs [5]. In the refugee population, NCDs can be aggravated by disruption and shortage of medication supplies, lack of access to care and acute exacerbations related to these challenges [6, 7].

In Lebanon, a country characterized by a highly privatized and expensive health care system, there are significant financial barriers to healthcare for the vulnerable refugee population [8], many of whom have pre-existing NCDs [9–11]. Although health care actors are present in Lebanon to respond to the needs of the refugee population, very little is done for NCDs which is still a high burden within this population. Poverty, often associated with refugee status, can contribute to the worsening of NCDs [12, 13]. Additionally, NCDs often lead to lower earning potential, decreased quality of life, increased morbidity and mortality, and a perpetuation of the poverty cycle [14, 15]. The prevalence of diabetes mellitus (DM) and hypertension (HTN) in the Syrian refugee population living in Lebanon has been recently estimated to be of 9.9 and 20.5%, respectively [9].

In order to meet the needs of the refugee population in the country, Médecins Sans Frontières (MSF) has been providing NCD care since 2013 at the primary healthcare level in the Shatila refugee camp, south of the capital Beirut. The model of care that MSF offers is a comprehensive package adapted to the context of the humanitarian crisis setting. Even though an innovative approach to the model of care was used, it was a significant challenge to successfully reach the target outcome goals for these diseases.

While a few studies and assessments have been published on the prevalence of NCDs among the Syrian refugees in Lebanon [9–11], to our knowledge, none has described what model of care is used to serve this population, nor the population’s characteristics nor the outcomes of care. Moreover, a recent systematic review looking at the evidence available on the effectiveness of interventions for NCDs in humanitarian contexts highlighted the enormous gap and limited quality of evidence on this topic [16]. These gaps included: the feasibility of NCD interventions in crisis settings, transparency in reporting of follow-up periods, full descriptions of the limitations of the studies as well as inadequacy of outcomes, most of which were self-reported [16]. Additionally, none of the studies included in this analysis were conducted in a refugee setting in Lebanon.

Therefore, the aim of this study was to address these gaps and add to the scarce evidence available by describing the model of care utilized to manage the Syrian refugee population affected by DM and/or HTN followed at the MSF NCD clinic in Shatila, Beirut, Lebanon, as well as to describe patient characteristics and assess treatment outcomes.

Methods
Study design
This was a descriptive retrospective cohort study carried out using routinely collected program data.

MSF NCD program
The NCD program is part of an integrated primary care program that MSF started in 2013 in Shatila, a refugee camp located in southern Beirut in Lebanon and home to an estimated 40,000 population, half of whom are refugees who have fled the war in Syria since 2011. Living conditions in the camp are challenged by poor infrastructure, insecurity, lack of health care coverage, and a significant level of poverty.

The MSF NCD program in Shatila serves the refugee and vulnerable host communities affected by the following NCDs: diabetes, hypertension, other cardiovascular diseases (CVD) -defined as one of the following: ischemic heart disease, heart failure, transient ischemic attack, cerebrovascular accident, or peripheral arterial disease-, chronic obstructive pulmonary disease, asthma, epilepsy, and hypothyroidism, with no age restriction. In 2017, the model of care for patients with DM and HTN was based on four main components: case management, patient support and education counseling (PSEC), integrated mental health, and health promotion (Table 1).

The model developed by MSF is an evolving, dynamic model, continuously adapting with the increasing knowledge of the context and the community cared for. For instance, provision of glucometers and PSEC were introduced mid-2016. Also in December 2016, task-shifting was introduced whereby patients with DM and/or HTN are seen interchangeably by the NCD nurse and doctor depending on criteria related to patients’ disease status (Table 1). Two doctors and one nurse average 35 and 32 NCD consultation per day respectively. This task-shifting and regular adaptation of the model resulted in a comprehensive, multidisciplinary approach to the management of DM and HTN, giving more time to explore patients’ needs, concerns and understanding of their condition. All services, including medications provided under this model of care, are free of charge.

Referrals to secondary and specialized care for DM and HTN complications are not an integral part of the model and only emergency cases are referred for hospitalisation due to limited capacity and resources. Therefore, disease complications such as macro- or micro-vascular complications are not addressed as part of our model. However, social workers are available to provide guidance to the patients in need of secondary referrals and to communicate
Table 1 MSF diabetes and hypertension model of care, Shatila primary care clinic, Beirut, Lebanon, 2013–2017

| Model of care component | Details |
|-------------------------|---------|
| **Case-Management** | Nurse's consultation consists of checking vital signs, fasting blood glucose and blood pressure measurements done at every consultation for DM and HTN patients. In addition, the NCD nurse checks vital signs for all scheduled NCD patients including the ones who present to see the doctor. Doctor's consultation is provided by trained general practitioners. Patients are not seen by specialist doctors at the MSF clinic at any time. If and when advised by the treating doctor, a patient with DM and/or HTN might be referred to a specialist as clinically indicated. All new patients are diagnosed by the doctors following MSF guidelines. DM is diagnosed with: a fasting plasma glucose level of $\geq 126$ mg/dl ($\geq 7$ mmol/L) and clinical symptoms at first visit, or at $\geq 2$ consecutive visits without clinical symptoms; or a random glucose level of $\geq 200$ mg/dl ($\geq 11.1$ mmol/L) at $\geq 2$ consecutive visits; or an HbA1C of $\geq 6.5\%$. HTN is diagnosed with: a SBP $> 140$ mmHg and/or a DBP $> 90$ mmHg at three clinical visits over 3 weeks; or a SBP $> 180$ mmHg and/or a DBP $> 110$ mmHg at first visit; or a SBP from 140 to 159 mmHg and/or DBP from 90 to 99 mmHg with a cardiovascular risk $> 20\%$ [WHO/ISH risk prediction chart] or a co-morbidity (cardiovascular disease, chronic kidney disease, DM). |
| **NCD nurse** | Doctor |
| New patients with DM and/or HTN | None | Every 1 to 2 months until they are controlled |
| Uncontrolled HTN | None | Every 1 to 2 months |
| Improving uncontrolled DM | Every 3 to 6 months | Every 2 to 4 months |
| Controlled DM or HTN | Every 6 months | Every 6 months |
| Patients with exacerbations | None | As needed |
| **Patient support and education counseling (PSEC)** | Drugs and glucometers are provided and renewed by the MSF pharmacist. Glucometers are provided for patients on insulin and pregnant women. |
| **Primary laboratory investigations carried out are:** | |
| * HbA1C every 3 months for uncontrolled DM patients and every 6 months for controlled DM patients. |
| * Total cholesterol, creatinine, and urine dipstick at enrollment (new patients) and annually or as needed. |
| All laboratory tests, including HbA1C were done in the same external quality assured reference laboratory. |
| **Mental health** | Mental health services are integrated in the NCD model of care. |
| **Health promotion** | Sessions are provided systematically and on a regular basis in waiting areas in groups by health promoters. They tackle general topics related to DM and HTN awareness. |

DBP diastolic blood pressure, DM diabetes mellitus, HTN hypertension, ISH international society of hypertension, MSF Medecins Sans Frontieres, NCD non-communicable diseases, PSEC Patient Education Support and Counseling, SBP systolic blood pressure, WHO world health organization.
with different healthcare stakeholders providing these services.

The protocols used in the management of DM and HTN patients were drafted by MSF based on guidelines of the WHO, the National Institute for Health and Care Excellence (NICE), and the European Society of Hypertension and Cardiology [17–19]. These MSF protocols and the monitoring of DM and HTN patients are continuously updated and adapted to respond to the programmatic and situational challenges, financial barriers faced by the community served and the local context of the ongoing humanitarian crisis. In fact, these patients struggle to meet their basic daily needs, have limited resources preventing them from following healthy lifestyle habits, have a low level of healthcare literacy, and frequently have to relocate their place of residence. In addition, some face security challenges related to their legal status preventing them from moving freely and attending the clinic.

In order to account for these challenges, visits were made comprehensive to include consultation, laboratory tests, drug delivery and PSEC all during the same day; the number of follow-up visits was reduced; longer supplies of medications were given (3 months for controlled patients); and task-shifting reduced the waiting time for patients. Clinical adaptations included setting the HbA1C target to be < 8% rather than < 7% (international guidelines), widening of the interval between HbA1C measurements (every 6 months rather than 3 months for controlled DM patients), and simplifying the list of medications by adopting the essential list of medications of the Lebanese Ministry of Health [20]. For instance, only two oral anti-diabetic agents were provided for Type-2 DM: metformin and glibenclamide.

Three types of insulin were available: pre-mixed (intermediate and short-acting insulin) 70/30 type, short-acting (regular) insulin and intermediate acting insulin. Newer oral anti-diabetic medications (DPP-4 inhibitors, SGLT-2 inhibitors, GLP-1 agonists) as well as long-acting (basal) and rapid-acting insulins were not available.

Antihypertensive medications included a thiazide diuretic (hydrochlorothiazide), angiotensin converting enzyme (ACE) inhibitors (enalapril, ramipril, and captopril), an angiotensin-2 receptor blocker (losartan), a beta-blocker (bisoprolol), a calcium channel blocker (amlodipine), as well as other diuretics (furosemide and spironolactone). Methyldopa was prescribed for pregnant hypertensive women when indicated.

As of the end of 2017, the NCD program was providing services for almost 3500 patients with an average of 166 new cases and 1800 consultations/month during 2017. Of all NCD patients on follow-up in 2017, 76% (n = 2644) were Syrian patients with DM and/or HTN. Although the NCD program is meant to serve the catchment area of Shatila and its surroundings, including host and refugee communities, the majority of the patients presenting to the clinic were Syrian refugees coming from outside of the catchment area.

**Study population**
This descriptive cohort included all Syrian patients: 1) with DM (types 1 and 2) or HTN, 2) who were enrolled in the MSF NCD program at any time up to 31 December 2017, and 3) who had at least one visit to the MSF Shatila clinic in 2017. For the treatment outcome analysis, patients had to: 1) be enrolled as of 30 June 2016 and be in the program for at least 6 months, 2) have ≥ two HbA1C tests for patients with DM and ≥ two visits with blood pressure (BP) measurements for patients with HTN recorded during their follow-up, with 3) the second HbA1C and/or BP recorded within 6 months of the first 1 ± 2 months. This specific sample of patients enrolled in the program and with a follow-up period restricted to ≥ 6 months and ≤ 18 months, was selected for the assessment of the treatment outcome to permit the analysis in a period where the program and the model of care were applied consistently with no major changes, which allows for an optimal reflection on the care delivered under these conditions.

**Data sources**
Data was retrieved from the electronic District Health Information System, version 2 (DHIS2) that captured patient-specific data. Trained personnel retrospectively recorded NCD program data extracted from the paper-based medical patients’ files in a standardized fashion into the DHIS2 system on a daily basis. This electronic system is currently used at country level in Lebanon for monitoring of other health services [21]. Variables included socio-demographic characteristics (age, gender, nationality, place of residence), program and clinical variables at first visit [follow-up time on the program, previously diagnosed disease, CVD as a co-morbidity, HbA1C, systolic blood pressure (SBP), diastolic blood pressure (DBP), number of medications and insulin use (at first and last visit), and clinical diagnosis]. Missing and outlier data were as much as possible verified from the source paper-based files when accessible.

**Treatment outcomes**
Outcomes of DM and HTN treatment were assessed after 6 months of care from enrollment. International consensus guidelines recommend a target HbA1C of < 7% for the majority of patients’ groups, and we aimed at providing our vulnerable population with the same standard of care. However, we were obliged to set an HbA1C target that is as close as possible to the international standards, taking into account the contextual challenges faced by this population in the access to care, medications and follow-up. Therefore, controlled hypertension was defined as a BP < 140/90 mmHg. Six months
HbA1C and BP values were compared to the first recorded (baseline) HbA1C and BP values for the same patients. The first HbA1C values recorded might not have been the ones collected at the enrollment visit. Therefore, patients were excluded from the outcome analysis if a first recorded HbA1C was dated >3 months after the enrollment date. Patients who did not present at their scheduled appointment within a 6 months’ time period were defined as lost to follow-up (LTFU).

**Statistical analysis**

Four main populations were defined based on their disease: patients with Type-1 DM only, patients with Type-2 DM only, patients with HTN only and patients with both DM (Type-1 or 2) and HTN. Descriptive statistics were used to describe the characteristics of the study population upon enrollment. Variables with >5% of their data missing were excluded.

For the treatment outcomes of DM patients (with or without HTN), the mean HbA1C at 6 months of care after enrollment was calculated and compared to the mean HbA1C at the first recorded visit. In addition, the proportion of patients with HbA1C <8% at 6 months was compared to that at the first recorded visit. HbA1C values <4% were excluded. For patients with HTN (with or without DM), the proportion of those with a BP <140/90 mmHg at 6 months was compared to the same proportion at first recorded visit. A range of ±2 months was applied to outcome periods since many patients at the NCD clinic in Shatila did not present at the exact date of their scheduled appointment; and also to account for possible delays in receiving the laboratory test results.

Wilcoxon signed rank tests or paired t-tests, and McNemar tests were used to compare the changes in the means and proportions. A p-value <0.05 was considered statistically significant and 95% confidence intervals were used. Data was exported from DHIS2 into Excel (Microsoft Corp, Redmond, Washington, USA) for data cleaning and analyzed using SPSS (USA, IBM corporation software, version 20).

**Results**

**Patient characteristics**

Of the total cohort, 2644 (76%) patients with DM or HTN had at least one visit to the MSF Shatila clinic in 2017 and were Syrian refugees. The majority (37%, n = 984) only had DM at their first visit, with Type-2 being the most prevalent (79%, n = 780) among them; 30% (n = 780) had HTN only and 33% (n = 880) had both DM and HTN as co-morbidities at their first visit (Fig. 1).

All patients, independent of their diagnosis, had a median age of 53 [Interquartile Range (IQR):45–61] and were predominantly females (63%, n = 1666). However, patients with Type-1 DM had a lower median age of 22 (IQR: 12–32), and were mostly males (57%, n = 116) (Table 2). The majority of patients (70%, n = 1789) came from outside of the catchment area. Almost all patients (97%, n = 2566) had been previously diagnosed. Among all patients, 14% (n = 375) had a cardiovascular comorbidity at their first visit. This figure was highest (20%, n = 158) amongst patients with HTN only compared to the other groups.

Among Type-2 DM patients, there were 73 patients (9%) on insulin at their first visit compared to 18% (n = 141) at their last visit in addition to one oral anti-diabetic medication (Table 2).

Patients with HTN presented with a mean SBP of 141 mmHg [Standard deviation (SD), 23.7] and a mean DBP of 86 mmHg (SD, 13.7) at their first recorded visit. Twenty-three percent (n = 361) were prescribed three or more anti-hypertensive medications at their first visit compared to a statistically significant increase to 38% (n = 610, p < 0.001) at their last visit.

The median follow-up period on the program was 13 months with 25% of the patients being on follow-up for more than 24 months. Patients with DM and HTN had a higher median period of follow-up (16 months) compared to the other categories, Type-2 DM being the lowest (11 months). Overall, LTFU was 16% (n = 426) for all patients over 6 months follow-up. Type-1 DM patients were the most retained on care (LTFU 9%, n = 18) compared to the other categories (Table 2).

**Patient outcomes**

Out of a total of 748 patients who were followed for at least 6 months till 31 December 2017, 65 (9%) and 305 (41%) patients met the inclusion criteria for DM and HTN respectively, and were included in the outcome analysis. Patients who did not meet the inclusion criteria (n = 683 and n = 443 for DM and HTN respectively) were mainly patients who did not have ≥2 HbA1C or BP recorded measures during the study period. Reasons could be possibly due to values not recorded in the electronic files or to missed appointments. The analysis was performed on 20 patients with Type-1 DM only, 23 patients with Type-2 DM only and 22 patients who had DM and HTN together; and on 153 patients with HTN only and 152 patients with DM and HTN for the HTN outcomes (Fig. 2).

Overall, 61% of patients with DM only and patients with DM and HTN (n = 40) had an HbA1C <8% at 6 months of care compared to 29% (n = 19) at baseline (p <0.001). A statistically significant increase in the proportion of patients with HbA1C <8% at 6 months compared to baseline was also observed in all subgroups of patients (Table 3). The majority of patients with Type-1 DM (55%, n = 11) had an HbA1C <8% at 6 months of care and the mean HbA1C at 6 months was 8.4% compared to a baseline mean of 9.3% (p = 0.022). In Type-2 DM patients, HbA1C mean at baseline was 9.4% compared to 6 months follow-up at 8.1% (p =
Patients with DM and HTN presented with the lowest baseline HbA1C mean (9.0%) and reached the lowest HbA1C target at 6 months (7.7%) compared to the others ($p = 0.003$), see Table 3.

Forty-nine percent ($n = 75$) of patients with HTN only reached the target BP at 6 months of care, compared to 27% ($n = 42$) at baseline ($p < 0.001$); while 52% ($n = 79$) of those with HTN and DM reached the target BP at 6 months versus 36% ($n = 55$) at baseline ($p = 0.006$) (Table 4). Patients with HTN only presented with a higher uncontrolled baseline SBP and DBP mean (145 and 89 mmHg) compared to the patients with DM and HTN (140 and 86 mmHg).

**Discussion**

To our knowledge, this is the first study describing a program of treatment for DM and HTN among Syrian refugees in Lebanon. It brings new evidence on the effectiveness of the program and treatment of DM and HTN patients in the humanitarian context of the Syrian crisis. Others have looked at the prevalence and access to NCD care in the region and Lebanon [9–11, 22], but there have been no description of the characteristics of this population, or of treatment outcomes.

This study also described the feasibility of a comprehensive, dynamic and multidisciplinary DM and HTN model operating at a primary care level that was continuously adapted to account for the programmatic and contextual challenges faced by the patients. It attracted many refugees to care, even from outside the catchment area, and demonstrated achievable outcomes deemed successful in a challenging crisis context and over a relatively short period of time (6 months). Additionally, it showed that the use of HbA1C, recommended as the method of choice for monitoring DM as compared to blood glucose measurements [23], is feasible in this context.

The characteristics of the Syrian refugees’ population seen in our clinic are comparable to the profile of patients with DM and/or HTN seen elsewhere in the Middle-East in terms of age and gender [22–25]. The fact that most of the patients came from outside of the catchment area may be explained by MSF’s successful and attractive comprehensive model of care that allowed patients to see the doctor, get their medications and glucometer if needed, carry out laboratory tests and receive education - all during the same visit and free of charge. This was especially important for patients with significant financial constraints. In that sense and unlike other NCD programs targeting different refugee contexts [24–26], the MSF model of care was adapted in a way to reduce the burden of visits on the patients. For instance, the model reduced the frequency of the visits to the minimum possible, decreased their length and avoided patients having to move outside of the clinic for tests or drugs, while still achieving high quality care.

While most patients at the MSF clinic had a previously diagnosed disease, which is an indicator of a relatively functional healthcare system in Syria [27], many were found to have uncontrolled DM and/or HTN at baseline. This implies that although aware of their disease, they had challenges accessing health care in Lebanon [5, 9]. For instance, even though all of the patients with Type-1 DM were on insulin when they were seen for their first visit to our program, the mean of their baseline HbA1C was high (9.3%). This is likely because they could not afford to pay for insulin, glucometers or test strips that are needed to monitor blood glucose levels.

The high baseline HbA1C mean of Type-2 DM patients could be an indicator of lack of access to adequate medications, regular medical follow-up and/or poor dietary options. Reasons could be financial barriers, lack of knowledge of the availability of services, or lack of medical awareness of the severity of their disease and the impact of a non-regular follow-up on long term complications. Despite a statistically significant drop in HbA1C in Type-1 DM patients after 6 months of care, they still had, on average, an uncontrolled HbA1C and the magnitude of the drop was still less than what was observed in Type-2 DM patients. This is to be expected.
Table 2 Characteristics of Syrian patients with diabetes and hypertension, Shatila primary care clinic, Beirut, Lebanon, 2013–2017

| Characteristics at first visit | DM-1 Only (n = 204) | DM-2 Only (n = 780) | HTN Only (n = 780) | DM + HTN (n = 880) | All patients (N = 2644) |
|-------------------------------|---------------------|---------------------|--------------------|-------------------|-------------------------|
| Age - year (median, IQR)      | 22 (12–32)          | 51 (44–58)          | 54 (47–62)         | 57 (51–63)        | 53 (45–61)              |
| Age categories - year - n (%) |                     |                     |                    |                   |                         |
| <18 y                         | 75 (36)             | 1 (< 1)             | 2 (< 1)            | 0 (0)             | 78 (3)                  |
| >= 18- < 40 y                 | 112 (55)            | 113 (14)            | 79 (10)            | 36 (4)            | 340 (13)                |
| >= 40- < 60 y                 | 16 (8)              | 506 (65)            | 454 (38)           | 513 (58)          | 1489 (56)               |
| >= 60 y                       | 1 (< 1)             | 160 (20)            | 245 (31)           | 331 (38)          | 737 (28)                |
| Gender - n (%)                |                     |                     |                    |                   |                         |
| Female                        | 88 (43)             | 459 (59)            | 534 (68)           | 585 (66)          | 1666 (63)               |
| Male                          | 116 (57)            | 321 (41)            | 246 (32)           | 295 (34)          | 978 (37)                |
| Place of residency - n (%)    |                     |                     |                    |                   |                         |
| In catchment area             | 55 (28)             | 218 (29)            | 271 (36)           | 221 (26)          | 765 (30)                |
| Outside catchment area        | 143 (72)            | 539 (71)            | 484 (64)           | 623 (74)          | 1789 (70)               |
| Previously diagnosed - n (%)  |                     |                     |                    |                   |                         |
| Yes                           | 199 (98)            | 733 (94)            | 760 (97)           | 874 (99)          | 2566 (97)               |
| No - newly diagnosed          | 5 (2)               | 47 (6)              | 20 (3)             | 6 (< 1)           | 78 (3)                  |
| Cardiovascular co-morbidity*  |                     |                     |                    |                   |                         |
| Yes                           | 2 (< 1)             | 75 (10)             | 158 (20)           | 140 (16)          | 375 (14)                |
| No                            | 202 (99)            | 705 (90)            | 622 (80)           | 740 (84)          | 2269 (86)               |
| HbA1C - % (mean (SD))         | 9.9 (2.1)           | 8.9 (2.1)           | NA                 | 8.7 (2.0)         | 9.0 (2.1)               |
| Blood pressure (mmHg)         |                     |                     |                    |                   |                         |
| Systolic blood pressure       | NA                  | NA                  | 142 (25)           | 139 (22.4)        | 141 (23.7)              |
| Diastolic blood pressure      | NA                  | NA                  | 87 (14.4)          | 84 (12.8)         | 86 (13.7)               |
| Number of prescribed medications |                   |                     |                    |                   |                         |
| 1                             | NA                  | NA                  | 249 (33)           | 335 (40)          | 584 (36)                |
| 2                             | NA                  | NA                  | 321 (42)           | 332 (40)          | 653 (41)                |
| >= 3                          | NA                  | NA                  | 193 (25)           | 168 (20)          | 361 (23)                |
| Insulin use*                  |                     |                     |                    |                   |                         |
| Yes                           | 204 (100)           | 73 (9)              | NA                 | 117 (13)          | 394 (21)                |
| No                            | 0 (0)               | 705 (91)            | NA                 | 751 (87)          | 1456 (79)               |
| Characteristics at last visit |                     |                     |                    |                   |                         |
| Number of prescribed medications |                   |                     |                    |                   |                         |
| 1                             | NA                  | NA                  | 167 (22)           | 219 (26)          | 386 (24)                |
| 2                             | NA                  | NA                  | 206 (39)           | 325 (38)          | 621 (38)                |
| >= 3                          | NA                  | NA                  | 300 (39)           | 310 (36)          | 610 (38)                |
| Insulin use*                  |                     |                     |                    |                   |                         |
| Yes                           | 204 (100)           | 141 (18)            | NA                 | 190 (22)          | 535 (29)                |
| No                            | 0 (0)               | 639 (82)            | NA                 | 690 (78)          | 1329 (71)               |
| Follow-up period while in the program - months (median, IQR) | 14 (6–23) | 11 (4–19) | 13 (5–25) | 16 (6–26) | 13 (5–24) |
| Lost to follow-up - n (%)     | 18 (9)              | 133 (17)            | 136 (17)           | 139 (16)          | 426 (16)                |

DM-1 type-1 diabetes, DM-2 type-2 diabetes, HTN hypertension, IQR interquartile range, NA not applicable, SD standard deviation

*Cardiovascular co-morbidity is defined as one of the following: ischemic heart disease, heart failure, transient ischemic attack, cerebrovascular accident, or peripheral arterial disease

*Calculated for patients with hypertension: 43 patients (2.6%) had this data missing in their files and were excluded from the calculation

*Calculated for patients with diabetes
given the particular physiological, psychosocial and behavioral challenges [28, 29] related to the Type-1 DM and patients’ specific circumstances, making them more difficult to control. In fact, they require a more frequent insulin regimen, with careful glucose monitoring and represent a younger population with a higher likelihood of non-compliance [30].

Studies looking at DM outcomes in Palestinian refugees have also shown that the proportion of patients with a controlled DM is higher in patients with Type-2 DM or DM and HTN compared to Type-1 DM [26], consistent with our findings. In addition, although there is no convincing evidence supporting improved efficacy with modern insulin [31, 32], if longer acting insulin were available in our clinics, they may have helped in better controlling challenging cases of Type-1 DM by improving compliance.

While it is expected that patients with DM and HTN would have more difficulties in achieving good outcomes, they actually reached a lower target HbA1C compared to the others. In this population, 20% were prescribed three or more drugs for their HTN at their first visit and 13% were already on insulin. These results would suggest that this patient group was more aware of their co-morbidities and had received better management at home and/or more health education over the years. This is the opposite of what one might think of in a crisis context, where polymedicated patients would more likely undergo treatment interruption, and suboptimal compliance. Fortunately, our results showed that these patients arrived better controlled for their DM and HTN and achieved a lower HbA1C target compared to other groups. This finding suggests that aiming for a lower HbA1C target in this population may be possible if clinically indicated. As in our study, another in a Palestinian refugee community showed that the highest proportion of patients with controlled DM was seen in patients with combined DM and HTN [26].

In contrast, Type-2 DM patients almost achieved the HbA1C target at 6 months of care. This raises the question of whether a lower HbA1C target could have been reached had we considered a longer study follow-up period. Yet, a study published in Kibera, Kenya, one of the largest informal settlements in Africa, showed that there was no improvement in DM outcome beyond 6 months of care [33]. However, fasting blood glucose was used in that study as a measure for the outcome and not HbA1C. Also, the context of the Syrian crisis might have

---

**Table 3** Six-month diabetes treatment outcome in Syrian patients, Shatila primary care clinic, Beirut, Lebanon, 2016–2017

|                     | Baseline HbA1C | Six month HbA1C | *p*-value *a* |
|---------------------|---------------|----------------|--------------|
| **HbA1C % [mean (SD); min-max]** |               |                 |              |
| Type-1 DM (n = 20)  | 9.3 (1.8); 6.0−12.6 | 8.4 (1.4); 6.7−12.3 | 0.022 |
| Type-2 DM (n = 23)  | 9.4 (2.5); 5.8−14.4 | 8.1 (1.8); 5.7−12.7 | 0.001 |
| DM and HTN (n = 22) | 9.0 (2.0); 5.7−12.9 | 7.7 (1.6); 5.5−11.8 | 0.003 |
| **HbA1C < 8% [n (%)]** |               |                 |              |
| Type-1 DM (n = 20)  | 4 (20)        | 11 (55)        | 0.016       |
| Type-2 DM (n = 23)  | 8 (35)        | 15 (65)        | 0.016       |
| DM and HTN (n = 22) | 7 (32)        | 14 (64)        | 0.039       |

*DM diabetes mellitus, HTN hypertension, SD standard deviation*

*p*-value <0.05 is statistically significant; Wilcoxon signed rank tests for mean and McNemar tests for proportions
levels and probably contributed to patients’ activities. Efforts by the PSEC and other health promotion activities are necessary to control their disease, despite education preventing patients from following lifestyle changes that are necessary to control their disease, despite education efforts by the PSEC and other health promotion efforts.

The protracted Syrian crisis has increased poverty levels and probably contributed to patients’ inability to purchase appropriate food for their conditions [34]. As well, restricted movements due to lack of legal documentation [34] and the living in urban settings may have prevented Syrians from exercising properly and accessing care appropriately contributing to harder control. Increasing psychological distress [35, 36] might also have impacted their motivation to adhere to treatment plans and to follow healthy lifestyle habits.

Although LTFU in patients with DM and/or HTN is a challenge in Shatila, it was only 16%, which is better than expected considering that most of the patients came from outside the catchment area, spent time on the road before getting to the clinic, and are believed to be constantly moving and changing addresses. Retention in care in Shatila seemed less than what was observed previously in the specific context of Palestinian refugees characterized by higher stability [23, 25] but much better than what was reported in other refugee contexts where LTFU in the DM and HTN patients was observed to be as high as 40% [33, 36, 37].

While this study brings new evidence, it also has limitations. It relied on the data collected into a newly implemented, customized DHIS2 software that was somewhat difficult to implement for monitoring and data analysis. Despite the fact that the data management team was thoroughly trained on the software’s use, there was considerable missing data for some variables which prevented their use in the study, body mass index for instance. In addition, although the sample size of the outcome cohort was relatively large, it presented only 9% of the initial outcome sample for DM and 41% for HTN. Reasons were not systematically documented and hence cannot be reported. However, it could partly be due to unrecorded measurements for HbA1C and BP values in the electronic files. It could also be due to missed appointments (anecdotally around 10 NCD patients per day). Although it is possible that this sample was prone to selection bias, we have no reason to believe that it would have led to better outcomes had a different sample been selected. In fact, the characteristics of the patients who were not included in the outcome analysis were similar to the ones who did not end up being part of it on the majority of their characteristics (data not shown). Therefore, we do not believe that selection bias, if present, would have led to an important regard on our results. The use of electronic health records for an efficient disease and programmatic performance follow-up are needed and were previously recommended for such contexts [23]; strengthening routine data systems used for monitoring in the field should be a high priority.

Another limitation was the 6 months follow-up for outcome assessment; it might have not been enough time to allow for stabilization of the outcome measures. Our outcome results were compared to targets that had been adapted to the humanitarian context and may not represent ideal targets for best control. In addition, our study lacks specific reporting on the frequency and severity of hypoglycemic episodes by the patients. Although information on hypoglycemia is not systematically documented in our program, patients for whom insulin will be introduced in their treatment plan, those who are on sulfonylureas or those who are in need of medication adjustments, are well educated by their doctors on the management of hypoglycemia and its risks and life threatening consequences. We do recommend for this to be followed-up in future studies specifically for patients with diabetes who are on insulin or on sulfonylureas. In addition to the above mentioned limitations, there is a possibility that our results were affected by regression to the mean. However, simulations applied on patients with more than two repeated measurements, whereby the mean of two baseline measurements was used to compare with a last measurement, did not lead to a

| SBP mmHg - [mean (SD); min-max] | Baseline BP | Six month BP | p-value |
|-------------------------------|-------------|--------------|---------|
| HTN (n = 153)                 | 145 (23.9); 100–220 | 129 (18.7); 100–190 | <0.001 |
| HTN and DM (n = 152)          | 140 (22.3); 80–210 | 132 (23.2); 80–260 | <0.001 |
| DBP mmHg - [mean (SD); min-max] |             |              |         |
| HTN (n = 153)                 | 89 (15.0); 60–130 | 83 (10.8); 50–110 | <0.001 |
| HTN and DM (n = 152)          | 86 (12.4); 50–110 | 82 (15.0); 50–180 | 0.011  |
| Controlled BP - [n (%)]       |             |              |         |
| HTN (n = 153)                 | 42 (27)     | 75 (49)      | <0.001 |
| HTN and DM (n = 152)          | 55 (36)     | 79 (52)      | 0.006  |

DBP diastolic blood pressure, DM diabetes mellitus, HTN hypertension, SBP systolic blood pressure, SD standard deviation

*p-value <0.05 is statistically significant; paired t-tests for mean and McNemar tests for proportions.
significant change in the final conclusion reached. This study, being descriptive in nature, lacks a control group to mitigate possible regression to the mean effect and confirm the true effectiveness of the program. It does however meet the STROBE criteria for cohort studies.

Conclusions
In conclusion, this study showed that a multidisciplinary approach to DM and HTN at the primary care level using contextualized and adapted treatment protocols was feasible in the context of a refugee camp like Shatila and achieved improved quality of care. It also showed that there might be possible to lower the treatment targets in this population to get it closer to the international guidelines. With the increasing burden of NCDs, this study suggests a comprehensive model of care for DM and HTN suitable and possibly replicable in similar contexts throughout the protracted crisis in the Middle-East and elsewhere.

Abbreviations
ACE: angiotensin converting enzyme; BP: blood pressure; CVD: cardiovascular disease; DBP: diastolic blood pressure; DHIS2: district health information system version 2; DM: diabetes mellitus; HTN: hypertension; IQR: interquartile range; LTFU: lost to follow-up; MSF: medecins sans frontieres; NCD: non-communicable disease; NICE: national institute for health and care excellence; PSEC: patient support and education counselling; SBP: systolic blood pressure; SD: standard deviation; WHO: world health organization

Acknowledgments
The authors would like to thank the NCD field management team in Shatila for their support of the study, as well as the Shatila data management team responsible of the NCD data entry in the DHIS2 program on a daily basis. Their availability for data cleaning and validation throughout the study was indispensable. We also thank the whole MSF Operational Research Center team in Luxembourg without which this study would have not been possible. Last, but not least, we thank our patients for their trust in MSF services.

Funding
The Foundation “Veuve Emile Metz-Tesch”, Luxembourg supported open access publications costs. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials
The datasets generated and/or analyzed during the current study are not publicly available due to the sensitivity of the context and the fact that this is data pertaining to refugees; datasets remain available from the corresponding author on reasonable request.

Authors’ contributions
MK, JE and CS designed and conceptualized the study with the support of the study team. MK and KM drafted the first version of the article. CL and KM did the statistical analyzes. CL led the acquisition of the data with the support of the study team. All authors contributed to the interpretation of data. All authors critically reviewed the draft of the article. All authors read and approved the final article. All authors agreed to be accountable for all aspects of the work.

Ethics approval and consent to participate
This study was exempted from approval from the Medecins Sans Frontieres Ethics Review Board as it used routine program data retrospectively collected with no individual data identifiers revealed or used; it was approved by the Institutional Ethics Board of the University of Balamand Faculty of Medicine and Medical Sciences in Lebanon (IRB/O/015–17/217).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Field mission, Médecins Sans Frontières, Operational Center Brussels, Shatila, Beirut, Lebanon. 2Lebanon branch office, Médecins Sans Frontières, Beirut, Lebanon. 3Lebanon mission, Médecins Sans Frontières, Operational Center Brussels, Beirut, Lebanon. 4Division of Endocrinology, Diabetes, and Metabolism, Faculty of Medicine and Medical Sciences, University of Balamand, Beirut, Lebanon. 5Operational Research Unit, Médecins Sans Frontières, Operational Center Brussels, Luxembourg City, Luxembourg. 6Department of Global Health, University of Washington, Seattle, Washington, USA.

Received: 12 August 2018 Accepted: 6 March 2019 Published online: 02 April 2019

References
1. World Health Organization (WHO). Global health observatory data, NCD mortality and morbidity. 2018. http://www.who.int/gho/ncd/mortality_morbidity/en/. Accessed 23 June 2018.
2. Research Triangle Institute (RTI) International. Non-communicable diseases factsheet. 2016. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC514294/. Accessed 10 July 2018.
3. World Health Organization (WHO). Global status report on non-communicable diseases. 2010. http://www.who.int/nmh/publications/ncd_report_full_en.pdf. Accessed 23 June 2018.
4. The government of Lebanon and the United Nations. Lebanon crisis response plan, 2017-2020. 2017. https://reliefweb.int/sites/reliefweb.int/files/resources/LCRP2018_EN_Full_report.pdf. Accessed 10 July 2018.
5. Holmes D. Chronic disease care crisis for Lebanon’s Syrian refugees. Lancet Diabetes Endocrinol. 2015;3(2):102.
6. Demaio A, Jamieson J, Horn R, Court d, Teller S. Non-communicable diseases in emergencies: a call to action. PLoS Curr. 2013;5.
7. Roberts B, Patel P, McKee M. Noncommunicable diseases and post-conflict countries. Bull World Health Organ; 2012; 90(5):22A.
8. Gammett MC. Partisan activism and access to welfare in Lebanon. Stud Comp Int Dev. 2011;46(1):70–9.
9. Doocy S, Lyles E, Hanquart B, Woodman M. Prevalence, care-seeking, and health service utilization for non-communicable diseases among Syrian refugees and host communities in Lebanon. Confl Health. 2016;10:21.
10. Dorcas Relief and Development. Needs Assessment on Older Syrian Refugees in Lebanon. 2016. https://lebanon.dorcascaritas.org/wp-content/uploads/sites/25/2016/09/Dorcas-Older-Persons-Needs-Assessment.pdf. Accessed 12 July 2018.
11. United Nations High Commission for Refugees (UNHCR). Health access and utilization survey among Syrian refugees in Lebanon. 2017. https://data2.unhcr.org/en/documents/download/61329. Accessed 27 June 2018.
12. Nielsen LW, Mohan D, Akukul JK, Mirembe AJ, Ahmed S, Koelmans TP, et al. Tackling socioeconomic inequalities and non-communicable diseases in low-income and middle-income countries under the sustainable development agenda. Lancet. 2018;391(10134):2036–46.
13. Philips M, Derderian K. Health in the service of state-building in fragile and conflict affected contexts: an additional challenge in the medical-humanitarian arena. Confl Health. 2015;9:13.
14. International Organization of Migration (IOM). Inter-agency multi-sector needs assessment. Phase one report - Secondary data review and analysis. 2014. https://reliefweb.int/sites/reliefweb.int/files/resources/13June2014-FINALMSNAPHASE1REPORT.pdf. Accessed 01 Aug 2018.
15. World Health Organization (WHO). Noncommunicable disease and poverty: the need for pro-poor strategies in the Western Pacific region: a review. 2007.
16. Ruby A, Knight A, Perel P, Blanchet K, Roberts B. The effectiveness of interventions for non-communicable diseases in humanitarian crises: a systematic review. PLoS One. 2015;10(9):e0138303.

17. European Society for Cardiology (ESC). ESC Clinical Practice Guidelines: European Society of Cardiology. 2016. http://www.escardio.org/Guidelines/Clinical-Practice-Guidelines. Accessed 26 July 2018.

18. National Institute for Health and Care Excellence (NICE). NICE guidelines: the National Institute for health and care excellence. 2016. https://www.nice.org.uk/guidance/conditions-and-diseases. Accessed 26 July 2018.

19. World Health Organization (WHO). Package of essential noncommunicable (PEN) disease interventions for primary health care in low-Resource Settings. 2010. www.who.int/nmh/publications/essential_ncd_interventions_lr_settings.pdf. Accessed 26 July 2018.

20. Republic of Lebanon, Ministry of Public Health. List of essential medicines Lebanon. 2014. https://www.moph.gov.lb/en/view/3123/%D9%84%D8%A7%D9%86%D8%AD%DA%A9-%D8%A7%D9%84%D9%85%DA%98%D9%A9-. Accessed 02 Aug 2018.

21. Youssef D, Khoury C, Allouch G, Haydar K, Jouny A, Zreik H, et al. Use of district health information system (DHIS-2) for real time surveillance: Lebanon 2017. Iproceedings. 2018;4(1):e10547.

22. Doocy S, Lyles E, Roberton T, Akhu-Zaheya L, Oweis A, Bumham G. Prevalence and care-seeking for chronic diseases among Syrian refugees in Jordan. BMC Public Health. 2015;15:1097.

23. Khader A, Farajallah L, Shahin Y, Hababeh M, Abu-Zayed I, Kochi A, et al. Cohort monitoring of persons with diabetes mellitus in a primary healthcare clinic for Palestine refugees in Jordan. Tropical Med Int Health. 2012;17(12):1569–76.

24. Alabed S, Guul A, Crighton C, Alahdab F, Fares M, Morad M, et al. An assessment of diabetes care in Palestinian refugee camps in Syria. Avicenna J Med. 2014;4(3):66–70.

25. Khader A, Farajallah L, Shahin Y, Hababeh M, Abu-Zayed I, Zachariah R, et al. Hypertension and treatment outcomes in Palestine refugees in United Nations relief and works agency primary health care clinics in Jordan. Tropical Med Int Health. 2014;19(10):1276–83.

26. Youssef S, Ali K, Ali K, Wafa A, Anthony DH, Jom N, et al. Clinical audit on the provision of diabetes care in the Primary Care Setting by United Nations relief and works Agency for Palestine Refugees in the near east (UNRWA). J Diabetes Mellitus. 2015;5(12):20–7.

27. Sen K, Al-Faisal W, AlSaleh Y, Shahin Y, Alkasem P, Peters AL. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care. 2014;37(7):2034–54.

28. Monaghan M, Helgeson V, Wiebe D. Type 1 diabetes in young adulthood. Curr Diabetes Rev. 2015;11(4):239–50.

29. Borus JS, Laffel LF. Adherence challenges in the management of type 1 diabetes in adolescents: prevention and intervention. Curr Opin Pediatr. 2010;22(4):405–11.

30. Laranjeira FO, de Andrade KRC, Figueiredo ACMG, Silva EN, Pereira MG. Long-acting insulin analogues for type 1 diabetes: an overview of systematic reviews and meta-analysis of randomized controlled trials. PLoS One. 2018;13(4):e0194801.

31. Hartman I. Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence. Clin Med Res. 2008;6(2):54–67.

32. Sobry A, Kizito W, Van den Bergh R, Tayler-Smith K, Isaakidis P, Cheti E, et al. Case load, management and treatment outcomes of patients with hypertension and/or diabetes mellitus in a primary health care programme in an informal setting. Tropical Med Int Health. 2014;19(11):47–57.

33. United Nations High Commission for Refugees (UNHCR). United Nations population and Children’s fund (UNFPA), World Food Programme (WFP). Vulnerability assessment of Syrian refugees in Lebanon, VASYR 2017. 2017.

34. Naja WJ, Aoun MP, El Khoury EL, Abdallah FJ, Haddad RS. Prevalence of depression in Syrian refugees and the influence of religiosity. Compr Psychiatry. 2016;68:78–85.

35. Danish Refugee Council Lebanon (DRC), Danish institute against torture. Needs and Barriers for Mental Health and Psychosocial Support among Syrian Refugees in Lebanon: Perspective for Future Interventions. 2018. https://flygtning.dk/media/4665743/mhpss-report.pdf. Accessed 28 July 2018.

36. Rue J, Isaakidis P, Reid T, Chy S, Keuley L, Arellano G, et al. Treating 4,000 diabetic patients in Cambodia, a high-prevalence but resource-limited setting: a 5-year study. BMC Med. 2009;7:33.